Ocugen, INC. (OCGN) — 8-K Filings

All 8-K filings from Ocugen, INC.. Browse 41 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (41)

Ocugen Files 8-K for Regulation FD Disclosure on March 24, 2026 — Mar 24, 2026
Ocugen, Inc. filed an 8-K on March 24, 2026, under Item 7.01, Regulation FD Disclosure, indicating they are publicly disclosing information that was not previou
Ocugen Reports Director/Officer Changes and Compensation — Dec 18, 2025 Risk: medium
Ocugen, Inc. filed an 8-K on December 18, 2025, reporting events as of December 12, 2025. The filing indicates changes related to the departure of directors or
Ocugen, Inc. Files 8-K on Financials — Nov 5, 2025 Risk: low
Ocugen, Inc. filed an 8-K on November 5, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The
Ocugen Terminates Material Definitive Agreement — Sep 18, 2025 Risk: medium
Ocugen, Inc. announced on September 16, 2025, the termination of a material definitive agreement. The company, incorporated in Delaware, filed this 8-K report o
Ocugen Enters Material Definitive Agreement — Sep 16, 2025 Risk: medium
Ocugen, Inc. entered into a Material Definitive Agreement on September 11, 2025. The filing does not disclose the specific nature or terms of this agreement, on
Ocugen Enters Material Definitive Agreement — Sep 5, 2025 Risk: medium
Ocugen, Inc. announced on August 29, 2025, that it entered into a material definitive agreement. The filing does not disclose specific details of the agreement,
Ocugen, Inc. Enters Material Definitive Agreement — Aug 11, 2025 Risk: medium
Ocugen, Inc. announced on August 8, 2025, that it entered into a material definitive agreement. The company, formerly known as Histogenics Corp, is incorporated
Ocugen Files 8-K on Financials — Aug 1, 2025 Risk: low
Ocugen, Inc. filed an 8-K on August 1, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibi
Ocugen Closes $100M Public Offering — Jul 30, 2025 Risk: medium
On July 29, 2025, Ocugen, Inc. announced the closing of its previously disclosed underwritten public offering. The company successfully raised approximately $10
Ocugen to Acquire Ocuphire Pharma for $100M — Jul 29, 2025 Risk: medium
Ocugen, Inc. announced on July 29, 2025, that it has entered into a definitive agreement to acquire all outstanding equity interests of Ocuphire Pharma, Inc. fo
Ocugen Faces Delisting Notice — Jul 1, 2025 Risk: high
Ocugen, Inc. filed an 8-K on July 1, 2025, to report a notice of delisting or failure to meet continued listing standards. The company is based in Malvern, Penn
Ocugen, Inc. Files 8-K: Material Agreement & Financials — Jun 23, 2025 Risk: medium
On June 22, 2025, Ocugen, Inc. entered into a material definitive agreement. The company also made a Regulation FD disclosure and filed financial statements and
Ocugen, Inc. Files 8-K Report — Jun 17, 2025 Risk: low
On June 16, 2025, Ocugen, Inc. filed an 8-K report detailing other events and financial statements. The company, incorporated in Delaware, is involved in biolog
Ocugen Files 8-K: Shareholder Vote, Other Events, Financials — Jun 5, 2025 Risk: low
On June 5, 2025, Ocugen, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders, other events, and financial statements and ex
Ocugen Files 8-K: Regulation FD & Financials — May 1, 2025 Risk: low
Ocugen, Inc. filed an 8-K on May 1, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's status an
Ocugen Reports Director/Officer Changes — Apr 25, 2025 Risk: medium
Ocugen, Inc. filed an 8-K on April 25, 2025, reporting events as of April 21, 2025. The filing pertains to the departure of directors or certain officers, elect
Ocugen Files 8-K: Routine Update — Apr 4, 2025 Risk: low
Ocugen, Inc. filed an 8-K on April 4, 2025, reporting other events and financial statements. The filing does not detail specific new events or financial figures
Ocugen, Inc. Files 8-K Reporting Other Events — Mar 3, 2025 Risk: low
Ocugen, Inc. filed an 8-K on March 3, 2025, reporting other events and financial statements. The filing does not contain specific details about new material eve
Ocugen Files 8-K: Other Events & Financials — Feb 12, 2025 Risk: low
On February 12, 2025, Ocugen, Inc. filed an 8-K report detailing other events and financial statements. The company, incorporated in Delaware, is involved in bi
Ocugen Files 8-K: Other Events & Financials — Jan 29, 2025 Risk: low
Ocugen, Inc. filed an 8-K on January 29, 2025, reporting other events and financial statements. The company, previously known as Histogenics Corp, is incorporat
Ocugen Faces Delisting Concerns — Jan 3, 2025 Risk: high
Ocugen, Inc. filed an 8-K on January 3, 2025, reporting a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard as of December 31, 2024
Ocugen Files 8-K for Other Events and Exhibits — Dec 3, 2024 Risk: low
Ocugen, Inc. filed an 8-K on December 3, 2024, to report other events and financial statements. The filing does not contain specific details about the nature of
Ocugen Board Shakeup & Officer Compensation Disclosed — Nov 15, 2024 Risk: medium
Ocugen, Inc. announced on November 14, 2024, a change in its board of directors. Dr. Anya Schiach, who served as a director, has resigned. The company also disc
Ocugen Files 8-K: Regulation FD & Exhibits — Nov 12, 2024 Risk: low
Ocugen, Inc. filed an 8-K on November 12, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain speci
Ocugen Files 8-K: Material Agreement, Financial Obligation, Equity Sale — Nov 8, 2024 Risk: medium
Ocugen, Inc. announced on November 6, 2024, that it entered into a material definitive agreement. The company also disclosed the creation of a direct financial
Ocugen Files 8-K on Operations and Financials — Nov 8, 2024 Risk: medium
Ocugen, Inc. filed an 8-K on November 8, 2024, reporting on its results of operations and financial condition. The filing also includes financial statements and
Ocugen, Inc. Files 8-K Report — Aug 13, 2024 Risk: medium
On August 13, 2024, Ocugen, Inc. filed an 8-K report, indicating a significant corporate event. The filing does not detail specific financial transactions or st
Ocugen Files 8-K: Routine Update — Aug 5, 2024 Risk: low
Ocugen, Inc. filed an 8-K on August 5, 2024, reporting other events and financial statements. The filing does not contain specific details about new material ev
Ocugen, Inc. Files 8-K with Material Agreements — Aug 1, 2024 Risk: medium
On July 31, 2024, Ocugen, Inc. entered into a Material Definitive Agreement, the specifics of which are detailed in the filing. The company also reported other
Ocugen Appoints New Auditor, Dismisses PricewaterhouseCoopers — Jul 8, 2024 Risk: medium
Ocugen, Inc. announced on July 2, 2024, a change in its certifying accountant. The company has dismissed PricewaterhouseCoopers LLP as its independent registere
Ocugen Files 8-K on Security Holder Vote — Jun 28, 2024 Risk: low
Ocugen, Inc. filed an 8-K on June 28, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain details about the spec
Ocugen Acquires Innovimmune Biotherapeutics for $15M — Jun 6, 2024 Risk: medium
Ocugen, Inc. announced on May 31, 2024, that it has entered into a definitive agreement to acquire all of the outstanding equity interests of Innovimmune Biothe
Ocugen Files 8-K: Rights, Bylaws, and Financials Updated — May 10, 2024 Risk: medium
Ocugen, Inc. filed an 8-K on May 10, 2024, reporting material modifications to the rights of security holders and amendments to its articles of incorporation or
Ocugen to Acquire Liminal BioSciences for $10M — Apr 8, 2024 Risk: medium
Ocugen, Inc. announced on April 8, 2024, that it has entered into a definitive agreement to acquire all outstanding equity interests of Liminal BioSciences Inc.
Ocugen Files 8-K for Operations and Financials — Apr 2, 2024 Risk: low
Ocugen, Inc. filed an 8-K on April 2, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhibits
Ocugen Restates Financials Due to Internal Control Review — Apr 1, 2024 Risk: medium
Ocugen, Inc. announced on April 1, 2024, that it will not rely on previously issued financial statements for the fiscal year ended December 31, 2023, and interi
Ocugen to Acquire Innovimmune for up to $150M — Mar 21, 2024 Risk: medium
Ocugen, Inc. announced on March 21, 2024, that it has entered into a definitive agreement to acquire all outstanding equity interests of Innovimmune Biotherapeu
Ocugen Files 8-K: Corporate Changes and Financial Updates — Mar 20, 2024 Risk: medium
Ocugen, Inc. filed an 8-K on March 20, 2024, reporting events as of March 15, 2024. The filing primarily concerns amendments to its articles of incorporation or
Ocugen Files 8-K Report — Mar 18, 2024 Risk: low
Ocugen, Inc. filed an 8-K on March 18, 2024, to report on other events and financial statements. The filing includes information about the company's operations
Ocugen Files 8-K on Feb 21, 2024, for Regulation FD Disclosure — Feb 21, 2024 Risk: low
Ocugen, Inc. filed an 8-K on February 21, 2024, under Regulation FD Disclosure and Financial Statements and Exhibits. The filing indicates a current report purs
Ocugen 8-K: Officer/Director Changes, Compensation & Exhibits — Jan 8, 2024
Ocugen, Inc. filed an 8-K on January 8, 2024, reporting an event that occurred on January 2, 2024. The filing indicates information related to the 'Departure of

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX